CD274 and non-small cell lung carcinoma: This prospective study enrolled 37 (88.1%) NSCLC patients with PD-L1 expression of at least 1%, of whom the mPFS was 1.9 months (95% CI 1.8–3.7), and the mOS was 9.9 months (95% CI 7.5–29.8) (78).